NHS and Sobi UK have come to an agreement that will give people living with haemophilia A in the UK increased access to Elocta, by lifting prior volume restrictions for the drug. Elocta is licensed by the European Commission in all age groups for treatment and prevention of bleeding in patients with haemophilia A. It
Our Director of Academies, Nikki Doyle, attended the NHS R&D Forum in Brighton last week. There was a choice of twenty different sessions over two days covering all aspects of the clinical trials environment in the UK at the present time. The first day started with a session which provided insight into perspectives by patients,
Two leading industry bodies within life sciences reported that the budget delivered by UK Chancellor Philip Hammond was broadly pro-business but contained some mixed news for the industry. News of an additional £20bn in funding for the NHS should be a benefit to companies in the pharma and healthcare sectors, particularly those contracting into the
Researchers have launched a £6 million trial investigating the potential of simvastatin as a treatment for multiple sclerosis. The Phase III MS-STAT2 trial will be funded by the MS Society, National Institute for Health Research, the National MS Society (US), the NHS and UK universities. The trial is set to involve over 1,000 people with
Diabetes is a common lifelong condition that is currently affecting the health of many people in the UK. It is estimated that there is currently 1 in 16 people living with the disease either diagnosed or undiagnosed. Under normal circumstances the pancreas produces insulin, a hormone that allows glucose to enter cells to be used
The regulatory body for the NHS in England and Wales has requested additional information from Genzyme prior to making a decision on the submission of Lemtrada. The National Institute for Health and Care Excellence (NICE) are currently unlikely to recommend the use of Genzyme’s Lemtrada (alemtuzumab) for relapsing, remitting multiple sclerosis, as a result of
Four Scottish health boards have partnered up with Pfizer to become the organisation’s second INSPIRE site within the UK, aimed at driving clinical research. The four health boards are NHS Grampian, Greater Glasgow & Clyde, Lothian and Tayside. The health boards have already heavily invested in the research endeavour through NHS Research Scotland (NRS), a
Scottish regulatory body, the Scottish Medicines Consortium (SMC), have approved Roche’s MabThera (rituximab) for the National Health Service (NHS) in Scotland. MabThera has been approved to treat two potentially life-threatening illnesses, GPA and MPA.
UK drugs watchdog, NICE, have endorsed the use of Lucentis on the NHS to treat visual impairment caused by diabetic macular oedema after Novartis submitted a revised patient access scheme (PAS) and new drug data. The National Institute for Health and Clinical Excellence published the final draft guidance after a rapid review of the original
England and Wales’ cost watchdog, NICE, yesterday reiterated their assessment that AstraZeneca’s breast cancer drug Faslodex does not represent good use of NHS funds and has not been proven to be better than current treatments. The National Institute for Health and Clinical Excellence (NICE) has published their final appraisal determination, saying that they do not
